Originally developed for type 2 diabetes, semaglutide has shown promising results in weight management for individuals with or without diabetes
Semaglutide treatment reduced the proportion of Cas3+ nuclei
While tirzepatide is not designed or approved for autoimmune disease treatment, preliminary research has identified potential anti-inflammatory properties associated with GLP-1 receptor agonists as a drug class
Daniel Drucker is a clinician-researcher and professor at the University of Toronto, and holds the Canada Research Chair in Regulatory Peptides and the Banting and Best Diabetes Centre-Novo Nordisk chair in Incretin biology
Alonso Martin takes a precision medicine approach to weight management, evaluating each patients metabolic health, laboratory results, and clinical objectives before recommending any course of treatment
Now, researchers and patients alike are looking toward the next evolution: Mazdutide and Retatrutide